News and Trends 22 Sep 2016
After only 6 months, Akarna seals the deal with Allergan for €44.8M upfront
Earlier this week, we announced the launch of a new diagnostic tool for NASH by the French company Genfit. Now, Ireland strikes back with the acquisition of Akarna with a €44.8M upfront payment. Akarna focuses on the development of drugs for Non-Alcoholic Steato-Hepatitis (NASH) and boasts to count with a potentially best-in-class therapeutic candidate still in preclinical trials. The […]
